FDA ships Form 483 to gener­ic drug gi­ant Dr. Red­dy’s due to equip­ment is­sues, oth­er ob­ser­va­tions

The FDA has is­sued a Form 483 let­ter to In­di­an gener­ic drug gi­ant Dr. Red­dy’s Lab­o­ra­to­ries, af­ter the agency found po­ten­tial­ly con­t­a­m­i­nat­ed drugs dur­ing an eight-day in­spec­tion from Oct. 19 at its site in Telan­gana, In­dia.

The 23-page let­ter cites nine ob­ser­va­tions, in­clud­ing poor­ly-cleaned equip­ment and dent­ed ma­chin­ery, caus­ing leak­ages and liq­uid spillages.

Residues of pre­vi­ous­ly man­u­fac­tured drug prod­ucts were found in man­u­fac­tur­ing equip­ment, lead­ing to po­ten­tial con­t­a­m­i­na­tion. The man­u­fac­tur­ers’ writ­ten spec­i­fi­ca­tions for test­ing aer­o­bic mi­cro­bial, yeast and mold counts for drug prod­ucts were al­so “de­fi­cient,” lead­ing to dis­crep­an­cies in colony counts, ac­cord­ing to FDA in­spec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER